Hopewell Therapeutics, founded in 2021 and based in Woburn, MA, is developing a differentiated lipid nanoparticle platform (ttLNPs) built on an expansive library of ionizable lipids and licensed IP from Tufts University. The company designs systemically administered LNPs that specifically target extrahepatic tissues and cells, with an initial internal pipeline focused on diseases of the lung. Hopewell is also exploring applications of its ttLNP platform for oncology, infectious diseases, rare genetic diseases, and neurological disorders. It has established multiple research relationships and partnerships with industry-leading companies to advance development and commercialization. Leadership includes Scientific Founder Qiaobing Xu, Ph.D. (CTO) and President & CEO Louis Brenner, M.D. The announced financing will fund both internal programs and external partnerships to advance genomic medicines based on the ttLNP platform.

Total raised

$25M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2023